Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Implantable cardioverter-defibrillators (ICDs) are recommended for primary prevention of sudden cardiac death (SCD) in patients with heart failure with reduced ejection fraction (HFrEF).
• Landmark trials supporting ICD use predated current guideline-directed medical therapies (GDMTs), prompting reevaluation of their role.
• Contemporary clinical practice necessitates a review of ICD efficacy and patient selection in the era of advanced heart failure management.

Purpose of the Study:

• To provide a comprehensive overview of current ICD recommendations for primary prevention in HFrEF.
• To analyze the impact of guideline-directed medical therapies (GDMTs) on SCD risk and ICD benefit.
• To offer pragmatic guidance for shared decision-making regarding primary ICD implantation.

Main Methods:

• Review of instrumental clinical trials and real-world data on SCD risk in HFrEF patients.
• Analysis of disparities in ICD utilization across diverse patient populations.
• Evaluation of the influence of contemporary GDMT on outcomes in patients with HFrEF.
• Examination of ongoing and future trials for improved SCD risk stratification.

Main Results:

• The role of ICDs for primary prevention is debated due to the evolution of GDMTs.
• Real-world SCD risk and ICD benefit may differ from landmark trial observations.
• Disparities in ICD use highlight potential inequities in access to care.
• Optimizing GDMT may alter the risk-benefit profile of ICDs in HFrEF.

Conclusions:

• Current ICD guidelines require reevaluation in the context of modern GDMT.
• Improved risk stratification tools are needed to identify HFrEF patients who will benefit most from ICDs.
• Shared decision-making, informed by updated evidence, is crucial for appropriate primary ICD implantation.